{"id":520,"date":"2020-11-11T20:10:00","date_gmt":"2020-11-11T11:10:00","guid":{"rendered":"https:\/\/idsc-gunma.jp\/congress\/jstm\/?p=520"},"modified":"2022-05-26T20:12:56","modified_gmt":"2022-05-26T11:12:56","slug":"%e8%86%b5%e8%87%93%e3%81%8c%e3%82%93%e6%b2%bb%e7%99%82%e3%82%92%e7%9b%ae%e6%8c%87%e3%81%97%e3%81%9fhsp70%e3%81%ae%e3%82%b3%e3%82%b7%e3%83%a3%e3%83%9a%e3%83%ad%e3%83%b3bag3%e3%81%ab%e5%af%be%e3%81%99","status":"publish","type":"post","link":"https:\/\/idsc-gunma.jp\/congress\/jstm\/%e8%86%b5%e8%87%93%e3%81%8c%e3%82%93%e6%b2%bb%e7%99%82%e3%82%92%e7%9b%ae%e6%8c%87%e3%81%97%e3%81%9fhsp70%e3%81%ae%e3%82%b3%e3%82%b7%e3%83%a3%e3%83%9a%e3%83%ad%e3%83%b3bag3%e3%81%ab%e5%af%be%e3%81%99\/","title":{"rendered":"\u81b5\u81d3\u304c\u3093\u6cbb\u7642\u3092\u76ee\u6307\u3057\u305fHsp70\u306e\u30b3\u30b7\u30e3\u30da\u30ed\u30f3BAG3\u306b\u5bfe\u3059\u308b\u30d2\u30c8\u5316\u6297\u4f53\u306e\u958b\u767a"},"content":{"rendered":"\n

\u4e00\u793e\uff09\u65e5\u672c\u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2\u5b66\u4f1a\u30cb\u30e5\u30fc\u30b9No.125\u3010\u5b66\u8853\u5831\u544a53\u3011<\/p>\n\n\n\n

\u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2\u306b\u95a2\u3059\u308b\u6700\u8fd1\u306e\u8a71\u984c53<\/p>\n\n\n\n

\u81b5\u81d3\u304c\u3093\u6cbb\u7642\u3092\u76ee\u6307\u3057\u305fHsp70\u306e\u30b3\u30b7\u30e3\u30da\u30ed\u30f3BAG3\u306b\u5bfe\u3059\u308b\u30d2\u30c8\u5316\u6297\u4f53\u306e\u958b\u767a<\/p>\n\n\n\n

\u7530\u6e15\u3000\u572d\u7ae0 (\u5bcc\u5c71\u5927\u5b66)<\/p>\n\n\n\n

BAG3 (BAG cochaperone 3)* \u306f\uff0c\u71b1\u30b7\u30e7\u30c3\u30af\u30bf\u30f3\u30d1\u30af\u8ceaHsp70\u306e\u30b3\u30b7\u30e3\u30da\u30ed\u30f3\u3067\u3042\u308a\uff0c\u7d30\u80de\u5897\u6b96\u4fc3\u9032\u3084\u30a2\u30dd\u30c8\u30fc\u30b7\u30b9\u6291\u5236\u7b49\uff0c\u3055\u307e\u3056\u307e\u306a\u6a5f\u80fd\u3092\u6709\u3059\u308b\uff0e\u307e\u305f\uff0c\u6570\u591a\u304f\u306e\u304c\u3093\u3067\u9ad8\u767a\u73fe\u3057\uff0c\u304c\u3093\u7814\u7a76\u9818\u57df\u306b\u304a\u3044\u3066\u6ce8\u76ee\u3055\u308c\u3066\u3044\u308b\u30bf\u30f3\u30d1\u30af\u8cea\u306e\u4e00\u3064\u3067\u3042\u308b1)<\/sup>\uff0e\u4ee5\u524d\u306b\uff0c\u30d2\u30c8\u81b5\u81d3\u304c\u3093\u306e\u7d30\u80de\u8cea\u306eBAG3\u306e\u767a\u73fe\u3068\u6b7b\u4ea1\u7387\u3068\u306e\u9593\u306b\u6b63\u306e\u76f8\u95a2\u304c\u3042\u308b\u3053\u3068\u3084\uff0c\u30d2\u30c8\u81b5\u81d3\u304c\u3093\u304b\u3089BAG3\u304c\u904a\u96e2\u3055\u308c\uff0c\u81b5\u81d3\u304c\u3093\u60a3\u8005\u306e\u672b\u68a2\u8840\u6e05\u30b5\u30f3\u30d7\u30eb\u3067\u305d\u308c\u304c\u691c\u51fa\u53ef\u80fd\u3067\u3042\u308b\u3053\u3068\u304c\u5831\u544a\u3055\u308c\u305f\uff0e\u3053\u306e\u304c\u3093\u304b\u3089\u904a\u96e2\u3055\u308c\u308bBAG3\u306f\uff0c\u30de\u30af\u30ed\u30d5\u30a1\u30fc\u30b8\u306e\u7d30\u80de\u819c\u4e0a\u306b\u3042\u308b\u30a4\u30f3\u30bf\u30fc\u30d5\u30a7\u30ed\u30f3\u3067\u8a98\u5c0e\u3055\u308c\u308b\u819c\u30bf\u30f3\u30d1\u30af\u8ceaIFITM2 (interferon induced transmembrane protein 2) \u3068\u7d50\u5408\u3059\u308b\uff0e\u3053\u306e\u523a\u6fc0\u306b\u3088\u308a\u30de\u30af\u30ed\u30d5\u30a1\u30fc\u30b8\u306f\u6d3b\u6027\u5316\u3057\uff0cIL-6\u304c\u653e\u51fa\u3055\u308c\uff0c\u3053\u308c\u304c\u81b5\u81d3\u304c\u3093\u306e\u5897\u6b96\u3068\u8ee2\u79fb\u3092\u4fc3\u9032\u3059\u308b\uff0e\u3053\u306e\u30d1\u30e9\u30af\u30ea\u30f3\u30eb\u30fc\u30d7*\u304c\u672c\u304c\u3093\u306e\u5897\u6b96\u306b\u91cd\u8981\u3067\u3042\u308b\u3053\u3068\u304c\u793a\u3055\u308c\u305f\uff0e\u307e\u305f\uff0c\u30de\u30a6\u30b9\u81b5\u81d3\u304c\u3093\u7d30\u80de\u79fb\u690d\u30e2\u30c7\u30eb\u306b\u304a\u3044\u3066BAG3\u306b\u5bfe\u3059\u308b\u30e2\u30ce\u30af\u30ed\u30fc\u30ca\u30eb\u6297\u4f53\u304c\u816b\u760d\u306e\u5f62\u6210\u3084\u8ee2\u79fb\u3092\u6709\u610f\u306b\u6291\u5236\u3059\u308b\u3053\u3068\u304c\u308f\u304b\u308a\uff0cBAG3\u306e\u30d1\u30e9\u30af\u30ea\u30f3\u30eb\u30fc\u30d7\u306e\u91cd\u8981\u6027\u304c\u78ba\u8a8d\u3055\u308c\u305f2)<\/sup>\uff0e<\/p>\n\n\n\n

\u3053\u306e\u3088\u3046\u306a\u80cc\u666f\u304b\u3089\uff0cRosati\u3089\u306e\u7814\u7a76\u30b0\u30eb\u30fc\u30d7\u306f\uff0c\u81b5\u81d3\u304c\u3093\u6cbb\u7642\u3092\u76ee\u6307\u3057\u305fBAG3\u306b\u5bfe\u3059\u308b\u30d2\u30c8\u5316\u6297\u4f53*\u306e\u958b\u767a\u3092\u884c\u3063\u305f3)<\/sup>\uff0eBAG3\u306e\u30bf\u30f3\u30d1\u30af\u8cea\u306e\u90e8\u5206\u914d\u52174\u7a2e\u985e (15-16\u30a2\u30df\u30ce\u9178) \u3092\u6297\u539f\u3068\u3057\u3066\u30de\u30a6\u30b9\u306e\u30e2\u30ce\u30af\u30ed\u30fc\u30ca\u30eb\u6297\u4f53\u3092\u4f5c\u88fd\u3057\u305f\u7d50\u679c\uff0cBAG3\u306e\u4e2d\u592e\u304b\u3089C\u672b\u7aef\u5074\u306b\u4f4d\u7f6e\u3059\u308b\u30d7\u30ed\u30ea\u30f3\u30ea\u30c3\u30c1\u30e2\u30c1\u30fc\u30d5 (PxxP)* \u3092\u542b\u3080PxxP\u30c9\u30e1\u30a4\u30f3\u306e\u90e8\u5206\u914d\u5217\u3092\u8a8d\u8b58\u3059\u308b\u6297\u4f53\u304c\u5f97\u3089\u308c\u305f\uff0e\u3053\u306e\u6297\u4f53\u306f\uff0c\u30ea\u30b3\u30f3\u30d3\u30ca\u30f3\u30c8BAG3\u30bf\u30f3\u30d1\u30af\u8cea\u306b\u3088\u308bCD14\u967d\u6027\u306e\u30d2\u30c8\u5358\u7403\u304b\u3089\u306eIL-6\u904a\u96e2\u3092\u9855\u8457\u306b\u6291\u5236\u3057\u305f\uff0e\u6b21\u306b\uff0c\u3053\u306e\u30e2\u30ce\u30af\u30ed\u30fc\u30ca\u30eb\u6297\u4f53\u306eCDR (\u76f8\u88dc\u6027\u6c7a\u5b9a\u9818\u57df)* \u3092\u57fa\u306b\u3057\u3066\u30d2\u30c8\u5316\u6297\u4f53*\u304c\u4f5c\u88fd\u3055\u308c\u305f (\u7279\u8a31: WO2017076878A1)\uff0e\u3053\u306e\u30d2\u30c8\u5316\u30e2\u30ce\u30af\u30ed\u30fc\u30ca\u30eb\u6297\u4f53\u306f\uff0c\u30de\u30a6\u30b9\u306e\u6297\u4f53\u3068\u540c\u69d8\u306bBAG3\u306e\u52b9\u679c\u3092\u4e2d\u548c\u3059\u308b\u6d3b\u6027\u3092\u793a\u3057\u305f\uff0e\u30cc\u30fc\u30c9\u30de\u30a6\u30b9\u3092\u7528\u3044\u305f\u30d2\u30c8\u81b5\u81d3\u304c\u3093\u7d30\u80de\u79fb\u690d\u30e2\u30c7\u30eb\u306b\u304a\u3044\u3066\uff0c\u672c\u30d2\u30c8\u5316\u6297\u4f53\u306f\u816b\u760d\u306e\u5f62\u6210\u3068\u8840\u7ba1\u65b0\u751f\u3092\u9855\u8457\u306b\u6291\u5236\u3057\uff0c\u3053\u306e\u4f5c\u7528\u306fDNA\u5408\u6210\u963b\u5bb3\u4f5c\u7528\u3092\u6709\u3059\u308b\u6297\u304c\u3093\u85ac\u30b2\u30e0\u30b7\u30bf\u30d3\u30f3\u306e\u52b9\u679c\u3088\u308a\u3082\u5f37\u304b\u3063\u305f\uff0e\u3053\u306e\u30d2\u30c8\u5316\u6297\u4f53\u3092\u30de\u30a6\u30b9\u306e\u9759\u8108\u5185\u306b\u6295\u4e0e\u3057\u305f\u3068\u304d\uff0c\u6297\u4f53\u306f\u816b\u760d\u90e8\u306b\u304a\u3044\u3066\u306e\u307f\u691c\u51fa\u3055\u308c\uff0c\u7d30\u80de\u8cea\u3067\u306eBAG3\u306e\u767a\u73fe\u30ec\u30d9\u30eb\u304c\u9ad8\u3044\u5fc3\u81d3\u3084\u809d\u81d3\u7d44\u7e54\u3067\u306f\u89b3\u5bdf\u3055\u308c\u306a\u304b\u3063\u305f\uff0e\u3053\u308c\u3089\u306e\u7d50\u679c\u304b\u3089\uff0cBAG3\u30d2\u30c8\u5316\u6297\u4f53\u306f\u304c\u3093\u7d30\u80de\u304b\u3089\u904a\u96e2\u3057\u305f\u7d30\u80de\u5916\u306b\u5b58\u5728\u3059\u308bBAG3\u306b\u53cd\u5fdc\u3059\u308b\u304c\u3001\u7d30\u80de\u5185\u306eBAG3\u3068\u306f\u53cd\u5fdc\u3057\u306a\u3044\u3053\u3068\u304c\u793a\u3055\u308c\u305f\uff0e\u4ee5\u4e0a\u306e\u6210\u7e3e\u304b\u3089\uff0cBAG3\u306b\u5bfe\u3059\u308b\u30d2\u30c8\u5316\u6297\u4f53\u306f\uff0c\u81e8\u5e8a\u306b\u304a\u3044\u3066BAG3\u3092\u6a19\u7684\u3068\u3057\u305f\u304c\u3093\u6cbb\u7642\u306b\u6709\u7528\u3067\u3042\u308b\u3053\u3068\u304c\u793a\u3055\u308c\u305f3)<\/sup>\uff0e<\/p>\n\n\n\n

\u8fd1\u5e74\uff0cRosati\u3089\u306e\u7814\u7a76\u30b0\u30eb\u30fc\u30d7\u306f\uff0c\u30de\u30a6\u30b9\u816b\u760d\u30e2\u30c7\u30eb\u306b\u304a\u3044\u3066BAG3\u30de\u30a6\u30b9\u30e2\u30ce\u30af\u30ed\u30fc\u30ca\u30eb\u6297\u4f53\u304cPD-1\u6297\u4f53\u3092\u7528\u3044\u305f\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u963b\u5bb3\u7642\u6cd5\u306e\u52b9\u679c\u3092\u5897\u5f37\u3059\u308b\u3053\u3068\u3092\u660e\u3089\u304b\u306b\u3057\u3066\u3044\u308b4)<\/sup>\uff0e\u307e\u305f\uff0cBAG3\u3068Hsp70\u3068\u306e\u76f8\u4e92\u4f5c\u7528\u304c\uff0c\u4f4e\u5206\u5b50\u5316\u5408\u72692,4-\u30c1\u30a2\u30be\u30ea\u30b8\u30f3\u30b8\u30aa\u30f3\u8a98\u5c0e\u4f53\u306b\u3088\u3063\u3066\u6291\u5236\u3055\u308c\u308b\u3053\u3068\u304c\u5831\u544a\u3055\u308c\u305f5)<\/sup>\uff0e\u3053\u308c\u3089\u306e\u57fa\u790e\u7814\u7a76\u3092\u57fa\u3065\u3044\u305f\uff0cBAG3\u306e\u4eca\u5f8c\u306e\u81e8\u5e8a\u306b\u304a\u3051\u308b\u5c55\u958b\u3092\u671f\u5f85\u3057\u305f\u3044\uff0e<\/p>\n\n\n\n

\u53c2\u8003\u6587\u732e<\/p>\n\n\n\n

  1. K\u00f6gel D, et al<\/em>. At the crossroads of apoptosis and autophagy: Multiple roles of the co-chaperone BAG3 in stress and therapy resistance of cancer. Cells, 9: 574, 2020.<\/li>
  2. Rosati A, et al<\/em>. BAG3 promotes pancreatic ductal adenocarcinoma growth by activating stromal macrophages. Nat Commun, 6: 8695, 2015.<\/li>
  3. Basile A, et al<\/em>. Development of an anti-BAG3 humanized antibody for treatment of pancreatic cancer. Mol Oncol, 13: 1388-99, 2019.<\/li>
  4. Iorio V, et al<\/em>. Combined effect of anti-BAG3 and anti-PD-1 treatment on macrophage infiltrate, CD8+<\/sup> T cell number and tumour growth in pancreatic cancer. Gut, 67: 780-2, 2018.<\/li>
  5. Terracciano S, et al<\/em>. Discovery and synthesis of the first selective BAG domain modulator of BAG3 as an attractive candidate for the development of a new class of chemotherapeutics. Chem Commun (Camb), 54: 7613-6, 2018.<\/li><\/ol>\n\n\n\n

    \u7528\u8a9e\u89e3\u8aac<\/p>\n\n\n\n

    *BAG3 (BAG cochaperone 3)\uff1aBAG3\u306f\uff0cHsc\/Hsp70 \u306eATPase\u30c9\u30e1\u30a4\u30f3\u3068\u76f8\u4e92\u4f5c\u7528\u3059\u308b\u30bf\u30f3\u30d1\u30af\u8cea\u3068\u3057\u3066\u540c\u5b9a\u3055\u308c\uff0cHsp70\u306e\u30b3\u30b7\u30e3\u30da\u30ed\u30f3\u3068\u3057\u3066\u6a5f\u80fd\u3059\u308b\uff0eBAG3\u306e\u4e3b\u306a\u8ee2\u5199\u56e0\u5b50\u306f\uff0c\u71b1\u30b7\u30e7\u30c3\u30af\u8ee2\u5199\u56e0\u5b50HSF1\u3067\u3042\u308a\uff0c\u9178\u5316\u30b9\u30c8\u30ec\u30b9\uff0c\u6e29\u71b1\uff0c\u91cd\u91d1\u5c5e\u7b49\uff0c\u7a2e\u3005\u306e\u30b9\u30c8\u30ec\u30b9\u306b\u3088\u308a\u8a98\u5c0e\u3055\u308c\u308b\uff0e\u307e\u305f\uff0cBAG3\u306f\uff0c\u7d30\u80de\u5897\u6b96\uff0c\u30a2\u30dd\u30c8\u30fc\u30b7\u30b9\uff0c\u7d30\u80de\u5206\u5316\uff0c\u7d30\u80de\u9aa8\u683c\u306e\u69cb\u7bc9\u3084\u30de\u30af\u30ed\u30aa\u30fc\u30c8\u30d5\u30a1\u30b8\u30fc\u7b49\u306e\u3055\u307e\u3056\u307e\u306a\u7d30\u80de\u6a5f\u80fd\u306e\u5236\u5fa1\u306b\u95a2\u4e0e\u3059\u308b\uff0e\u307e\u305f\uff0cBAG3\u306f\uff0c\u304c\u3093\uff0c\u30df\u30aa\u30d1\u30c1\u30fc\uff0c\u52a0\u9f62\u306b\u4f34\u3046\u795e\u7d4c\u5909\u6027\u75be\u60a3\u7b49\uff0c\u591a\u69d8\u306a\u75be\u60a3\u306b\u95a2\u9023\u3059\u308b\u3053\u3068\u304c\u77e5\u3089\u308c\u3066\u3044\u308b\uff0e<\/p>\n\n\n\n

    *\u30d1\u30e9\u30af\u30ea\u30f3\u30eb\u30fc\u30d7\uff1a\u7d30\u80de\u304b\u3089\u7269\u8cea\u3092\u5206\u6ccc\u3059\u308b\u69d8\u5f0f\u306f\uff0c\u4ee5\u4e0b\u306e\uff13\u3064\u304c\u3042\u308b\uff0e\u2460\u30a8\u30f3\u30c9\u30af\u30ea\u30f3 (\u5185\u5206\u6ccc)\uff1a\u5206\u6ccc\u7269\u304c\u8840\u7ba1\u3092\u4ecb\u3057\u3066\u9060\u65b9\u306e\u7d30\u80de\u306b\u4f5c\u7528\uff0c\u2461\u30d1\u30e9\u30af\u30ea\u30f3 (\u508d\u5206\u6ccc)\uff1a\u5206\u6ccc\u7269\u304c\u8fd1\u304f\u306e\u7d30\u80de\u306b\u4f5c\u7528\uff0c\u2462\u30aa\u30fc\u30c8\u30af\u30ea\u30f3 (\u81ea\u5df1\u5206\u6ccc)\uff1a\u5206\u6ccc\u7269\u304c\u81ea\u3089\u306e\u7d30\u80de\u306b\u4f5c\u7528\uff0e\u30d1\u30e9\u30af\u30ea\u30f3\u30eb\u30fc\u30d7\u3068\u306f\uff0c\u5206\u6ccc\u3059\u308b\u7d30\u80de\u3068\u8fd1\u304f\u306e\u53d7\u3051\u53d6\u308b\u7d30\u80de\u3068\u306e\u9593\u3067\u7269\u8cea\u306e\u3084\u308a\u53d6\u308a\u3092\u7e70\u308a\u8fd4\u3057\u884c\u3046\u3053\u3068\u3067\u3042\u308b\uff0e<\/p>\n\n\n\n

    *\u30d2\u30c8\u5316\u6297\u4f53 (humanized antibody)\uff1a\u30de\u30a6\u30b9\u3067\u4f5c\u88fd\u3057\u305f\u30e2\u30ce\u30af\u30ed\u30fc\u30ca\u30eb\u6297\u4f53\u306eCDR\u306e\u30a2\u30df\u30ce\u9178\u914d\u5217\u3092\u30d2\u30c8\u6297\u4f53\u306e\u914d\u5217\u306b\u7f6e\u304d\u63db\u3048\u3066\u4f5c\u88fd\u3055\u308c\u305f\u3082\u306e\uff0e\u907a\u4f1d\u5b50\u5de5\u5b66\u3092\u7528\u3044\u3066\uff0c\u30d2\u30c8\u6297\u4f53H \u9396\uff0cHCDR1-3\u3068L\u9396\uff0cLCDR1-3\u3092\u767a\u73fe\u3055\u305b\u3066\u30d2\u30c8\u5316\u6297\u4f53\u3092\u69cb\u7bc9\u3059\u308b (CDR-grafting)\uff0e\u6297\u4f53\u306e\u30d2\u30c8\u5316\u306b\u3088\u308a\uff0c\u30d2\u30c8\u306b\u6295\u4e0e\u3057\u305f\u6642\u306b\u514d\u75ab\u53cd\u5fdc\u304c\u6291\u3048\u3089\u308c\u308b\uff0e<\/p>\n\n\n\n

    *\u30d7\u30ed\u30ea\u30f3\u30ea\u30c3\u30c1\u30e2\u30c1\u30fc\u30d5 (PxxP)\uff1a\u30d7\u30ed\u30ea\u30f3\u306b\u5bcc\u3080\u30da\u30d7\u30c1\u30c9\u914d\u5217\u3067\uff0c\u6700\u5c0f\u306e\u30b3\u30f3\u30bb\u30f3\u30b5\u30b9\u914d\u5217\u306f Pro-X-X-Pro (PxxP)\uff0e\u3053\u306e\u30e2\u30c1\u30fc\u30d5\u3092\u542b\u3080\u30c9\u30e1\u30a4\u30f3\u306f\uff0cSH3 (Src-homology 3) \u30c9\u30e1\u30a4\u30f3\u3068\u7d50\u5408\u3059\u308b\uff0eBAG3\u3068IFITM2 (interferon induced transmembrane protein 2) \u306b\u306f\u5404\u3005\uff0cPxxP\u30c9\u30e1\u30a4\u30f3\u3068SH3\u30c9\u30e1\u30a4\u30f3\u304c\u5b58\u5728\u3059\u308b\uff0eBAG3\u3068IFITM2\u306f\uff0c\u3053\u308c\u3089\u306e\u30c9\u30e1\u30a4\u30f3\u3092\u4ecb\u3057\u3066\u6a5f\u80fd\u7684\u306b\u7d50\u5408\u3059\u308b\uff0e<\/p>\n\n\n\n

    *CDR (complementarity determining region,\u76f8\u88dc\u6027\u6c7a\u5b9a\u9818\u57df)\uff1aCDR\u306f\uff0c\u6297\u4f53\u306e\u69cb\u9020\u4e2d\u306b\u3042\u308b\u6297\u539f\u3068\u7d50\u5408\u3059\u308b\u90e8\u4f4d\u3067\u3042\u308b\uff0e\u6297\u539f\u7279\u7570\u6027\u3092\u767a\u63ee\u3059\u308b\u305f\u3081\u306b\u3053\u306e\u9818\u57df\u306e\u69cb\u9020\u304c\u591a\u7a2e\u591a\u69d8\u306b\u5909\u5316\u3059\u308b\uff0e\u6297\u4f53\u306eH\u9396\u306b\u3042\u308bHCDR1\uff0cHCDR2\u3068HCDR3\uff0cL\u9396\u306eLCDR1\uff0cLCDR2\u3068LCDR3\u306e\u9818\u57df\u3067\u6297\u539f\u3092\u7279\u7570\u7684\u306b\u8a8d\u8b58\u3059\u308b\uff0e<\/p>\n","protected":false},"excerpt":{"rendered":"

    \u4e00\u793e\uff09\u65e5\u672c\u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2\u5b66\u4f1a\u30cb\u30e5\u30fc\u30b9No.125\u3010\u5b66\u8853\u5831\u544a53\u3011 \u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2\u306b\u95a2\u3059\u308b\u6700\u8fd1\u306e\u8a71\u984c53 \u81b5\u81d3\u304c\u3093\u6cbb\u7642\u3092\u76ee\u6307\u3057\u305fHsp70\u306e\u30b3\u30b7\u30e3\u30da\u30ed\u30f3BAG3\u306b\u5bfe\u3059\u308b\u30d2\u30c8\u5316\u6297\u4f53\u306e\u958b\u767a \u7530\u6e15\u3000\u572d\u7ae0 (\u5bcc\u5c71\u5927\u5b66) BAG […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"vkexunit_cta_each_option":"","footnotes":""},"categories":[5],"tags":[],"class_list":["post-520","post","type-post","status-publish","format-standard","hentry","category-report"],"_links":{"self":[{"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/posts\/520","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/comments?post=520"}],"version-history":[{"count":1,"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/posts\/520\/revisions"}],"predecessor-version":[{"id":521,"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/posts\/520\/revisions\/521"}],"wp:attachment":[{"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/media?parent=520"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/categories?post=520"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/tags?post=520"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}